© Website designed by Alasdair Coles, 2012

Key Group Publications

2014; 2013

2012; 2011; 2010; 2009; 2008

2005-2007; 2000-2004; Pre 2000


Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Jones J, Compston DA, Coles A. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2014 May 21. [Epub ahead of print] PubMed PMID: 24849515. pdf Kousin-Ezewu O, Azzopardi L, Parker RA, Tuohy O, Compston A, Coles A, Jones J. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology. 2014 May 16.. [Epub ahead of print] PubMed PMID: 24838790. pdf


Azzopardi L, Thompson SA, Harding KE, Cossburn M, Robertson N, Compston A, Coles AJ, Jones JL. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub 2013 Dec 24. PubMed PMID: 24368840. pdf Jones JL, Thompson SA, Loh P, Davies JL, Tuohy OC, Curry AJ, Azzopardi L, Hill-Cawthorne G, Fahey MT, Compston A, Coles AJ. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20200-5. Epub 2013 Nov 26. PubMed PMID: 24282306; PubMed Central PMCID: PMC3864306. pdf McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7 pdf


Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Oct 31. doi:pii: S0140-6736(12)61769- 3. 10.1016/S0140-6736(12)61769-3. [Epub ahead of print]   pdf Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; for the CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Oct 31. doi:pii: S0140-6736(12)61768-10.1016/S0140- 6736(12)61768-1   pdf Button T, Altmann D, Tozer D, Dalton C, Hunter K, Compston A, Coles A, Miller D. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult Scler. 2012 Apr 5. pdf Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology. 2012 Apr 3;78(14):1069-78. Epub 2012 Mar 21 pdf back to top


Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 2012 Mar;83(3):298-304. Epub 2011 Nov 5 pdf Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011 Dec 8;118(24):6299-305. Epub 2011 Sep 29. Jones JL, Dean AF, Antoun N, Scoffings DJ, Burnet NG, Coles AJ.'Radiologically compatible CLIPPERS' may conceal a number of pathologies. Brain. 2011 Aug;134(Pt 8):e187. Epub 2011 Jun 7 Oomatia A, Young A, Hall FC, Jayne DR, Coles AJ, Shenker N, Zandi MS, Mulford M Multiple Cranial Neuropathies, A Rare Complication Of Systemic Sclerosis. Clin Exp Rheumatol 29(1):191-191 Jan 2011 Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab  versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011 Apr;10(4):338-48. pdf Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011 Apr;258(4):686-8. pdf back to top


Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010 Aug;133(Pt 8):2232-47 Epub 2010 Jul 21. pdf Somerfield J, Hill-Cawthorne GA, Lin A, Zandi MS, McCarthy C, Jones JL,Willcox M, Shaw D, Thompson SA, Compston AS, Hale G, Waldmann H, Coles AJ. A Novel Strategy To Reduce the Immunogenicity of Biological Therapies. J Immunol. 2010 Jul 1;185(1):763-8. Epub 2010 Jun 2. pdf back to top


Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010 Jan;30(1):99-105. Epub 2009 Sep 10. pdf Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009 Jul;119(7):2052-61 pdf back to top


Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (CAMMS223 Trial Investigators). Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal Medicine. 2008 Oct 23;359(17):1786-801. pdf back to top


Cox A, Coles AJ [joint first author], Nortje J, Bradley P, Menon D. An investigation of auto-reactivity after head injury. J Neuroimmunol. 2006 May;174(1-2):180-6  pdf Coles AJ, Cox A, Le Page E, Jones J, Trip S, Deans J, Seaman S, Miller D, Hale G, Waldmann H, Compston DAS. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy in relapsing-remitting and secondary progressive disease. J Neurology 2006 January; 253 (1): 98-108 pdf Coles AJ, Thompson S, Cox AL, Curran S, Gurnell EM, Chatterjee VK. Dehydroepiandrosterone (DHEA) replacement in patients with Addison’s disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. European Journal of Immunology 2005 Dec;35(12):3694-703 pdf back to top


Cox A, Thompson S, Jones J, Robertson V, Hale G, Waldmann H, Compston A, Coles A. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.  European Journal of Immunology. 2005 Nov;35(11):3332-42 pdf Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg.  2004 Jun;106(3):270-4. Coles A, Deans J, Compston.  Multiple sclerosis trial precipitates divorce. J Neurol Neurosurg Psychiatry. 2001; 70: 135 back to top


Coles A, Wing M, Smith S, Corradu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A.  Pulsed monoclonal antibody treatment and autoimmune thyroid disease. Lancet. 1999 Nov 13; 354: 1691-5 pdf Coles A J, Wing M, Molyneux P, Paolillo A, Davies C, Hale G, Miller D, Waldmann H, Compston A.  Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.  Annals of Neurology. 1999 Sept; 46 (3): 296-304 pdf Paolillo A, Coles A, Molyneux P, Gawne-Cain M, MacManus D, Barker G, Compston A, Miller D. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath-1H.  Neurology. 1999 Sep 11; 53(4): 751-7 O'Riordan JI, Gawne Cain M, Coles A, Wang L, Compston DA, Tofts P, Miller DH T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Multiple Sclerosis. 1998 Oct;4(5):408-12. Coles AJ, Wing MG, Compston DA. Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy. Multiple Sclerosis. 1998 Jun;4(3):232-8. Tubridy N, Coles AJ, Molyneux P, Compston DA, Barkhof F, Thompson AJ, McDonald WI, Miller DH.  Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain. 1998 Feb;121 ( Pt 2):225-31 Gawne-Cain ML, O'Riordan JI, Coles A, Newell B, Thompson AJ, Miller DH.  MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences. J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):197-203. Moreau T, Coles A, Wing M, Thorpe J, Miller D, Moseley I, Issacs J, Hale G, Clayton D, Waldmann H, Compston A. Campath-1H in multiple sclerosis. Multiple Sclerosis. 1996;1:357-65. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119:225-37 pdf Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 1994 Jul 30;344(8918):298-30 back to top
ABOUTHome Alemtuzumab Group Members Research For People with MS Contact News YOUR HEADING TEXT Alasdair Coles, Joanne Jones and Alastair Compston Cambridge Neuroimmunology